Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
Small molecule drug, Tagrisso (Osimertinib) taken alongside chemotherapy has showed a strong improvement in progression-free survival for patients with EGFR (epidermal growth factor receptor)-mutated advanced lung cancer, a phase 3 study has revealed.
Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer compared to just chemotherapy...
Lonza and Agennix have made a tactical alliance over the Phase III production of a non-small cell lung cancer therapy in the hopes it will improve the chance of joint manufacturing after the commerical launch.
Helix BioPharma and BioVectra have signed a deal for the
manufacture of Helix's new lung cancer drug for clinical trials - a
move that strengthens the already existing relationship between the
two Canadian firms.
Scientists have demonstrated that a tumour suppressor gene could
actually stimulate tumour progression, which if confirmed, could
raise possibilities of using the gene as a novel prognostic
indicator of tumour aggressiveness.
US scientists think they have come up with a novel test that
indicates how a patient with early-stage lung cancer will respond
to chemotherapy, giving the opportunity to tailor treatment to the
A recent paper has emerged, which details results of a clinical
laboratory test and its ability to accurately predict drug response
in lung cancer. The test gives way to the possibility of less
Scientists have found an unusual lung-cancer tumour-suppressor
gene, which was shown to restore the inactivated gene slowing the
growth of tumour cells. Its importance in cancers of the lung and
head and neck may make it a viable...
Researchers in the US have shed light on how tumours acquire
resistance to kinase inhibitors. The discovery may help explain the
acquired resistance observed in chemotherapy, which currently
blights existing cancer treatments.
Hana Biosciences announced today the clinical trial initiation of
PT-523 to evaluate this compound as a single agent in relapsed
non-small cell lung cancer (NSCLC). Lung cancer continues to carry
the poorest prognosis of cancer,...
Allos Theraputics have initiated a phase 1 study of its
investigational drug PDX (pralatrexate) that has so far proved
effective against non-small cell lung cancer (NSCLC). This
treatment has the potential to surpass Methotrexate...
Researchers from medical charity Cancer Research UK have discovered
a new gene that protects against lung cancer, according to a study
published today in the journal Proceedings of the National Academy